Ovarian cancer with high-level focal ERBB2 amplification responds to trastuzumab and pertuzumab

Epithelial ovarian cancer (EOC) is usually diagnosed at an advanced stage and significantly contributes to cancer mortality in women. Despite multimodal treatment associating chemotherapy and surgery, most patients ultimately progress and require palliative systemic therapy. In EOC, the efficacy of...

Descripción completa

Detalles Bibliográficos
Autores principales: Thouvenin, Laure, Charrier, Mélinda, Clement, Sophie, Christinat, Yann, Tille, Jean-Christophe, Frigeri, Mauro, Homicsko, Krisztian, Michielin, Olivier, Bodmer, Alexandre, Chappuis, Pierre O., McKee, Thomas A., Tsantoulis, Petros
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165411/
https://www.ncbi.nlm.nih.gov/pubmed/34095423
http://dx.doi.org/10.1016/j.gore.2021.100787

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165411/
https://www.ncbi.nlm.nih.gov/pubmed/34095423
http://dx.doi.org/10.1016/j.gore.2021.100787

Ejemplares similares